Atopic dermatitis (AD) is a persistent inflammatory skin disease marked by intense rash and itching. Traditional treatments for moderate-to-severe AD, such as methotrexate, often cause significant side effects. Dupilumab, a biologic therapy that inhibits IL-4 and IL-13 cytokines, presents a safer alternative. A comprehensive literature review corroborates the safety and effectiveness of dupilumab in AD patients with cancer, though the current evidence is limited, necessitating further research. Dupilumab's targeted mechanism on IL-4 and IL-13 may also positively influence the tumor microenvironment, potentially boosting anti-tumor responses. Future studies should focus on assessing dupilumab's long-term safety, efficacy, and economic viability across larger and more diverse populations to better understand its dual role in managing both cancer and AD.